Oncological perspective on Kaposi sarcoma: A single-centre experience

Year 2025, Volume: 38 Issue: 1, 9 - 14, 29.01.2025

Ali Kaan Güren , İclal Çakır Nargiz Majidova , Nadiye Sever , Erkam Kocaaslan , Pınar Erel , Yeşim Ağyol , Abdussamet Çelebi , Rukiye Arıkan , Selver Işık , Murat Sarı , Özlem Ercelep , Vedat Bayoğlu , Osman Köstek

https://doi.org/10.5472/marumj.1627569

Abstract

Objective: Kaposi sarcoma (KS) presents as a multifocal angioproliferative disease with distinct four subtypes, including classical,
AIDS-related(epidemic), endemic, and iatrogenic. The rarity of the disease and the clinically different characteristics of the subtypes
have led to insufficient experience in treatment and follow-up. Based on this, we aim to investigate the clinicopathological features and
treatment options of the KS patients treated and followed up in our clinic.
Patients and Methods: The study included 66 patients diagnosed with KS by histopathological examination. KS subtypes, stages,
distribution of lesions, chemotherapy regimens and efficacy of chemotherapy regimens were recorded. The efficacies of paclitaxel and
pegylated liposomal doxorubicin (PLD) were compared. Kaplan-Meier and Cox regression analyses were used for statistical analyses.
Results: Classical KS was the most common subtype (n=50), followed by AIDS-related (n=14) and iatrogenic (n=2) types. 32 patients
received systemic treatment. In different lines, paclitaxel was administered to 32 patients and PLD to 12 patients. Disease control rate
(DCR) was 78.1% for paclitaxel and 75% for PLD, while overall response rate (ORR) was 68.7% and 58.3%, respectively.
Conclusion: Paclitaxel and PLD demonstrated efficacy in controlling aggressive KS. However, larger studies are warranted to further
validate these findings and optimize chemotherapy strategies.

Keywords

Kaposi sarcoma , Classic Kaposi sarcoma , AIDS-related Kaposi sarcoma , Pegylated liposomal doxorubicin , Paclitaxel

References

• Dupin N. Update on oncogenesis and therapy for Kaposi sarcoma. Curr Opin Oncol 2020;32:122-8. doi: 10.1097/ CCO.000.000.0000000601. PMID: 31815777.
• Kaposi Idiopathisches multiples Pigmentsarkom der Haut. Arch. f. Dermat 1872; 4: 265-73. doi.org/10.1007/ BF01830024
• Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994 ;266:1865-9. doi: 10.1126/ science.7997879. PMID: 7997879.
• Ganem D, Neill US. A conversation with Don Ganem. J Clin Investi 2014;124:464-5. doi: 10.1172/jci73101.
• Hutt MS. Classical and endemic form of Kaposi’s sarcoma. A review. Antibiot Chemother (1971). 1983;32:12-7.
• Mitsuyasu RT. AIDS-related Kaposi’s sarcoma: a review of its pathogenesis and treatment. Blood Rev 1988;2:222-31. doi: 10.1016/0268-960x(88)90011-2.
• Stein ME, Spencer D, Ruff P, Lakier R, MacPhail P, Bezwoda WR. Endemic African Kaposi’s sarcoma: clinical and therapeutic implications. 10-year experience in the Johannesburg Hospital (1980-1990). Oncology 1994 ;51:63-9. doi: 10.1159/000227312.
• Brambilla L, Genovese G, Berti E, et al. Diagnosis and treatment of classic and iatrogenic Kaposi’s sarcoma: Italian recommendations. Ital J Dermatol Venerol 2021;156:356-65. doi: 10.23736/S2784-8671.20.06703-6.
• Lebbe C, Garbe C, Stratigos AJ, et al. European Dermatology Forum (EDF), the European Association of Dermato- Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Kaposi’s sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer 2019;114:117-27. doi: 10.1016/j.ejca.2018.12.036.
• Mangusan RF, Ekwede I, Widell A. CE: HIV-associated Kaposi sarcoma in the combination antiretroviral therapy era. Am J Nurs 2022;122:32-40. doi: 10.1097/01. NAJ.000.090.1848.07128.92.
• Ramaswami R, Lurain K, Yarchoan R. Oncologic treatment of HIV-associated Kaposi sarcoma 40 Years on. J Clin Oncol 2022;40:294-306. doi: 10.1200/JCO.21.02040. PMID: 34890242; PMCID: PMC8769148.
• Fatahzadeh M. Kaposi sarcoma: review and medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:2-16. doi: 10.1016/j.tripleo.2011.05.011.
• Brambilla L, Romanelli A, Bellinvia M, et al. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br J Dermatol 2008;158:1339-44. doi: 10.1111/j.1365- 2133.2008.08517.x.
• Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIVassociated Kaposi’s sarcoma with paclitaxel. Lancet 1995;346(8966):26-8. doi: 10.1016/s0140-6736(95)92654-2.
• Di Lorenzo G, Kreuter A, Di Trolio R, et al. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi’s sarcoma: a multicenter study. J Invest Dermatol 2008 ;128:1578-80. doi: 10.1038/sj.jid.5701215.
• Cooley T, Henry D, Tonda M, Sun S, O’Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Oncologist 2007;12:114-23. doi: 10.1634/ theoncologist.12-1-114.
• Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010;116:3969-77. doi: 10.1002/cncr.25362.
• Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 2002;20:3236-41. doi: 10.1200/JCO.2002.12.038.